Virus therapy takes on hard-to-treat ovarian cancer
NCT ID NCT06618235
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called THEO-260, a virus designed to attack cancer cells, in people with advanced ovarian cancer that no longer responds to platinum chemotherapy. About 44 participants will receive different doses of the virus through an IV to find a safe dose and see if it can shrink tumors. The goal is to control the disease, not cure it, as ongoing management is expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE ENDOMETRIOID FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centro Integral Oncológico Clara Campal (CIOCC) Hospital
RECRUITINGMadrid, Spain
-
Imperial College Healthcare NHS Trust, Hammersmith Hospital
RECRUITINGLondon, United Kingdom
-
Oxford University Hospitals NHS Foundation Trust, Churchill Hospital
RECRUITINGOxford, United Kingdom
-
The Beatson West of Scotland Cancer Centre
RECRUITINGGlasgow, Scotland, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
- Can a smart drug home in on Hard-to-Treat cancers?